Antibodies Archives

morphosys genmab janssen cancer immunotherapy

News and Trends 28 Jan 2019

Update: US District Court Rules Against MorphoSys’ Cancer Immunotherapy Patents

Update (01/02/2019): MorphoSys has agreed to end its long-running legal battle with Genmab and Janssen, after the US District Court of Delaware declared three of its cancer immunotherapy patents invalid. MorphoSys began the dispute over Darzalex (daratumumab), Genmab and Janssen’s approved antibody therapy for the blood cancer multiple myeloma. MorphoSys alleged that Darzalex infringed on three of […]

January 28, 2019 - 3 minutesmins - By Dani Bancroft

sanofi biomunex cancer therapy bispecific antibodies 1

News and Trends 15 Jan 2019

Sanofi Obtains License for French Company’s Antibody Engineering Platform

Sanofi has signed a licensing deal with French biotech Biomunex, whose antibody technology has the potential to develop new immunotherapy treatments for cancer and infectious diseases. Sanofi will give Biomunex an upfront payment, along with further installments upon achieving key development milestones. The amounts have not been disclosed. Biomunex is able to make a wide variety […]

January 15, 2019 - 2 minutesmins - By Jonathan Smith

Best in Biotech 24 Dec 2018

Looking Back on 2018: Our 10 Most Popular Interviews

As 2018 draws to a close and our thoughts are torn between holiday plans and what the new year may bring, we decided to look back and revisit the people and the stories that attracted our readers the most during the year. These were well received the first time around, so we thought you might […]

December 24, 2018 - 8 minutesmins - By Helen Albert

News and Trends 12 Dec 2018

Antibody Hitting Tumor Self-Destruct Button Passes Phase I

A first-in-class antibody cancer treatment, from the French company Netris Pharma, has shown good safety and anti-tumor effects in a phase I trial in patients with advanced solid tumors. The antibody met the trial’s primary objective of good tolerability in the 19 recruited patients. In addition, the antibody helped to stabilize the disease and shrink […]

December 12, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 27 Nov 2018

Berlin Biotech Raises €24M to Progress Septic Shock Candidate to Clinic

Adrenomed closed a €24M Series D round to fund further development of its antibody drug that treats septic shock by preventing excessive fluid loss and preserving the blood vessel walls. Wellington Partners and HBM Healthcare Investments, who specialize in investing in life science companies, joined existing shareholders to lead the fundraising round. Sepsis and resulting […]

November 27, 2018 - 3 minutesmins - By Helen Albert

den bosch netherlands lava therapeutics cancer immunotherapy

Startup Scout 23 Nov 2018

This Biotech Arms Tumor-Busting Cells to Treat Cancer

In the medieval city of ‘s-Hertogenbosch, the Netherlands, Lava Therapeutics is developing a cancer immunotherapy that arms a rare type of immune cell called gamma delta T cells. Mission: Develop antibodies that recruit innate immune cells near tumors and activate them to kill cancer cells. T cells are immune cells that have a strong potential […]

November 23, 2018 - 3 minutesmins - By Jonathan Smith

News and Trends 31 Oct 2018

Multiple Myeloma Antibody Therapy Achieves Positive Phase III Results

An antibody therapy for the blood cancer multiple myeloma achieved positive results at Phase III, decreasing the risk of the disease getting worse and patient death by 45% in a Phase III trial. The blockbuster antibody daratumumab, developed by Janssen using a license from the Danish company Genmab, was given to patients in combination with […]

October 31, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 5 Oct 2018

Lab-Grown Antivenom Shows Potential for Curing Black Mamba Snakebite

Antivenoms could one day be made in the lab instead of in animals. Researchers from the Technical University of Denmark have neutralized black mamba venom in mice with lab-grown human antibodies for the first time. Snakebite is a serious problem, causing the deaths of around 100,000 people every year, and about three times that number […]

October 5, 2018 - 3 minutesmins - By Jonathan Smith

More News! 19 Sep 2018

Argenx Attracts Huge €250M Investment Following Positive Phase II Trial

Belgian biotech Argenx raised over €250M in public investment on the Nasdaq Stock Market after announcing positive Phase II results for its lead autoimmune drug candidate. The company now plans to progress efgartigimod, an antibody fragment inspired by llama antibodies, to Phase III trials for treatment of the autoimmune blood disease primary immune thrombocytopenia (ITP). […]

September 19, 2018 - 2 minutesmins - By Jonathan Smith

Interview 24 Jul 2018

Meet the Dutch Scientists who Invented Keytruda, “The President’s Drug”

Known for curing US President Jimmy Carter’s cancer, Keytruda continues to benefit many other cancer patients. The inventors told us their story, from the drug’s early days to their current role as executives of the biotech unicorn Aduro. Since 2014, the cancer drug Keytruda, also known as pembrolizumab, continues to be widely sought after due […]

July 24, 2018 - 6 minutesmins - By Editorial Team

News and Trends 20 Jul 2018

Belgian Biotech Completes First Trial with New Drug for Diabetic Macular Edema

Belgian biotech ThromboGenics has conducted the first clinical trial of an antibody to treat one of the world’s leading causes of vision loss. Results from the Phase I/II trial demonstrate the safety and tolerability of a new kind of antibody treatment for diabetic macular edema. The trial focused on injecting the THR-317 antibody, which is directed against […]

July 20, 2018 - 2 minutesmins - By External Contributor

News and Trends 9 Jul 2018

Swedish Alzheimer’s Treatment Slows the Disease in Phase II Trial

BioArctic, based in Stockholm, has clinical results showing its antibody treatment that targets amyloid plaques, a hallmark of Alzheimer’s disease, can slow the disease’s progression. The trial tested the antibody in 856 patients with early-stage Alzheimer’s disease with plaques of amyloid-beta protein in their brains, which is considered a common hallmark of the disease. Results taken at […]

July 9, 2018 - 3 minutesmins - By Alexander Burik

Knowledge hub

Categories

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Approaches

Therapeutic areas

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Antibodies

Update: US District Court Rules Against MorphoSys’ Cancer Immunotherapy Patents

Sanofi Obtains License for French Company’s Antibody Engineering Platform

Looking Back on 2018: Our 10 Most Popular Interviews

Antibody Hitting Tumor Self-Destruct Button Passes Phase I

Berlin Biotech Raises €24M to Progress Septic Shock Candidate to Clinic

This Biotech Arms Tumor-Busting Cells to Treat Cancer

Multiple Myeloma Antibody Therapy Achieves Positive Phase III Results

Lab-Grown Antivenom Shows Potential for Curing Black Mamba Snakebite

Argenx Attracts Huge €250M Investment Following Positive Phase II Trial

Meet the Dutch Scientists who Invented Keytruda, “The President’s Drug”

Belgian Biotech Completes First Trial with New Drug for Diabetic Macular Edema

Swedish Alzheimer’s Treatment Slows the Disease in Phase II Trial

Subscribe to our newsletter to get the latest biotech news!

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!